Irosustat

DRUG2 trials

Sponsors

Imperial College London

Conditions

Breast NeoplasmsLocally Advanced Breast CancerMetastatic Breast Cancer

Phase 2

A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth

TerminatedNCT01662726

Imperial College LondonBreast Neoplasms

Start: 2012-08-31End: 2014-12-31Updated: 2016-03-14

A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.

CompletedNCT01785992

Imperial College LondonLocally Advanced Breast Cancer, Metastatic Breast Cancer

Start: 2012-10-31End: 2014-12-31Updated: 2015-03-24

Related Papers

A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IRIS) – Trial Results.

Journal of Clinical Oncology2016-05-206 citations

The effects of the first in class steroid sulfatase inhibitor Irosustat on FLT uptake and Ki67 in estrogen receptor positive early breast cancer: Results of the perioperative IPET study.

Journal of Clinical Oncology2016-05-201 citations